TriangleNCT03269136 · OUTCOME
Part 1: Concentration of Soluble Cytokines in Serum
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Picogram per milliliter
- Interval / dispersion
- Full Range
- Time frame
- Part 1: C1 (0, 2, 4 & 8 hours [h] post dose on Day [D] 1, 24h post dose on D2, 72h post dose on D3); Part 1.1, 1C & 1D: C0 (0, 2, 4 & 8h post dose on D1, 24h post dose on D2); C1 (0, 2, 4 & 8h post dose on D1, 24h post dose on D2, 72h post dose on D3)
What was measured
The concentration of Interleukin-2, Interleukin-6, Interferon-gamma and tumor necrosis factor-alpha were measured in this outcome measure. Cycle = C.
Analysis population: The Pharmacodynamic (PD)/Biomarker analysis set included all enrolled participants with at least 1 of the PD/Biomarkers evaluated at pre- and/or post-dose. Here, "Number Analyzed" signifies participants evaluable for specified rows.
Groups in this outcome
Part 1: PF-06863135 0.1 mcg/kg IV
Participants with relapsed/refractory advanced multiple myeloma (MM) received PF-06863135 at a dose of 0.1 microgram/kilogram (mcg/kg) as an intravenous (IV) infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
Part 1: PF-06863135 0.3 mcg/kg IV
Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 0.3 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
Part 1: PF-06863135 1 mcg/kg IV
Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 1 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
Part 1: PF-06863135 3 mcg/kg IV
Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 3 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
Part 1: PF-06863135 10 mcg/kg IV
Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 10 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
Part 1: PF-06863135 30 mcg/kg IV
Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 30 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
Part 1: PF-06863135 50 mcg/kg IV
Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 50 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
Part 1: PF-06863135 80 mcg/kg SC
Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 80 mcg/kg as a subcutaneous (SC) injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
Part 1: PF-06863135 130 mcg/kg SC
Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 130 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
Part 1: PF-06863135 215 mcg/kg SC
Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 215 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
Part 1: PF-06863135 360 mcg/kg SC
Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 360 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
Part 1: PF-06863135 600 mcg/kg SC
Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 600 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
Part 1: PF-06863135 1000 mcg/kg SC
Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 1000 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
Part 1.1: PF-06863135 Priming Cohort Q1W SC
Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 600 mcg/kg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 1000 mcg/kg as a SC injection every week (Q1W) on Day 1, 8, 15 and 22 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
Part 1.1: PF-06863135 Priming Cohort Q2W SC
Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 600 mcg/kg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 1000 mcg/kg as a SC injection every 2 weeks (Q2W) on Day 1 and 15 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
Part 1C: PF-06863135 + Lenalidomide SC
Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 32 mcg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 44 mcg as a SC injection Q1W on Day 1, 8, 15 and 22 along with lenalidomide at dose of 15 mg, orally, daily on Days 1-21 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
Part 1D: PF-06863135 + Pomalidomide SC
Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 32 mcg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 44 mcg as a SC injection Q1W on Day 1, 8, 15 and 22 along with pomalidomide at dose of 4 mg, orally, daily on Days 1-21 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 5 |
| Part 1: PF-06863135 50 mcg/kg IV | 6 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 7 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
Reported measurements
Interleukin-2: Cycle 0; 0 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 7 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
Interleukin-2: Cycle 0; 2 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 7 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 2.10 | Not reported | 2.1 | 9.1 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 2.10 | Not reported | 2.1 | 55.0 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.10 | Not reported | 2.1 | 10.5 | Not reported |
Interleukin-2: Cycle 0; 4 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 7 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 2.70 | Not reported | 2.1 | 19.7 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 3.60 | Not reported | 2.1 | 247.4 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.10 | Not reported | 2.1 | 6.5 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.40 | Not reported | 2.1 | 20.9 | Not reported |
Interleukin-2: Cycle 0; 8 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 14.30 | Not reported | 2.1 | 487.8 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 17.90 | Not reported | 2.1 | 118.1 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.10 | Not reported | 2.1 | 82.0 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.10 | Not reported | 2.1 | 1063.8 | Not reported |
Interleukin-2: Cycle 0; 24 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 7 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 2.10 | Not reported | 2.1 | 12.2 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 2.10 | Not reported | 2.1 | 15.5 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.10 | Not reported | 2.1 | 2.3 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.10 | Not reported | 2.1 | 7.1 | Not reported |
Interleukin-2: Cycle 1; 0 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 5 |
| Part 1: PF-06863135 50 mcg/kg IV | 6 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 5.00 | Not reported | 5.0 | 24.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 5.00 | Not reported | 5.0 | 37.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 2.1 | 5.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
Interleukin-2: Cycle 1; 2 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 4 |
| Part 1: PF-06863135 50 mcg/kg IV | 4 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 12.50 | Not reported | 5.0 | 112.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 2.1 | 5.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
Interleukin-2: Cycle 1; 4 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 4 |
| Part 1: PF-06863135 50 mcg/kg IV | 5 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.50 | Not reported | 5.0 | 6.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 53.00 | Not reported | 5.0 | 80.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 83.00 | Not reported | 21.0 | 202.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 12.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 5.50 | Not reported | 5.0 | 7.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 2.1 | 6.7 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 2.10 | Not reported | 2.1 | 34.9 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 2.10 | Not reported | 2.1 | 2.2 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
Interleukin-2: Cycle 1; 8 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 2 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 4 |
| Part 1: PF-06863135 50 mcg/kg IV | 5 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 11 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 11.0 | Not reported | 5.0 | 43.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 5.00 | Not reported | 5.0 | 52.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 50.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 8.50 | Not reported | 5.0 | 15.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 12.50 | Not reported | 5.0 | 39.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 2.1 | 20.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 2.10 | Not reported | 2.1 | 55.7 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 2.10 | Not reported | 2.1 | 18.3 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.10 | Not reported | 2.1 | 2.4 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
Interleukin-2: Cycle 1; 24 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 5 |
| Part 1: PF-06863135 50 mcg/kg IV | 5 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 5.00 | Not reported | 5.0 | 9.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 2.1 | 5.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 2.10 | Not reported | 2.1 | 5.8 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 2.10 | Not reported | 2.1 | 2.7 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 2.10 | Not reported | 2.1 | 8.0 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.10 | Not reported | 2.1 | 7.4 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.10 | Not reported | 2.1 | 7.2 | Not reported |
Interleukin-2: Cycle 1; 72 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 1 |
| Part 1: PF-06863135 30 mcg/kg IV | 5 |
| Part 1: PF-06863135 50 mcg/kg IV | 5 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 5.00 | Not reported | 5.0 | 14.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 2.1 | 5.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 2.10 | Not reported | 2.1 | 2.1 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.10 | Not reported | 2.1 | 4.7 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.10 | Not reported | 2.1 | 3.5 | Not reported |
Interleukin-6: Cycle 0; 0 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 7 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 2.00 | Not reported | 2.0 | 4.9 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 2.00 | Not reported | 2.0 | 17.4 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.00 | Not reported | 2.0 | 2.9 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.00 | Not reported | 2.0 | 2.5 | Not reported |
Interleukin-6: Cycle 0; 2 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 7 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 2.10 | Not reported | 2.0 | 10.8 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 2.00 | Not reported | 2.0 | 60.5 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.00 | Not reported | 2.0 | 3.6 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.00 | Not reported | 2.0 | 2.2 | Not reported |
Interleukin-6: Cycle 0; 4 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 7 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 11.50 | Not reported | 3.2 | 63.6 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 10.40 | Not reported | 2.0 | 843.7 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 3.75 | Not reported | 2.0 | 17.1 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 5.25 | Not reported | 2.0 | 88.5 | Not reported |
Interleukin-6: Cycle 0; 8 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 7 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 88.40 | Not reported | 14.8 | 1821.1 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 129.90 | Not reported | 2.0 | 1028.0 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 3.70 | Not reported | 2.2 | 670.4 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.00 | Not reported | 2.0 | 169.8 | Not reported |
Interleukin-6: Cycle 0; 24 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 201.40 | Not reported | 15.1 | 428.4 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 122.70 | Not reported | 2.6 | 2396.8 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 8.50 | Not reported | 5.3 | 1651.0 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 33.60 | Not reported | 4.7 | 882.2 | Not reported |
Interleukin-6: Cycle 1; 0 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 5 |
| Part 1: PF-06863135 50 mcg/kg IV | 6 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 7.00 | Not reported | 5.0 | 9.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 6.50 | Not reported | 5.0 | 8.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 12.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 5.00 | Not reported | 5.0 | 32.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 5.00 | Not reported | 5.0 | 7.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 32.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 6.50 | Not reported | 5.0 | 23.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 2.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 2.00 | Not reported | 2.0 | 28.1 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 59.20 | Not reported | 9.6 | 370.9 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 24.50 | Not reported | 2.1 | 212.3 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 9.30 | Not reported | 2.0 | 219.5 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.00 | Not reported | 2.0 | 146.8 | Not reported |
Interleukin-6: Cycle 1; 2 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 4 |
| Part 1: PF-06863135 50 mcg/kg IV | 4 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 6.00 | Not reported | 5.0 | 7.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 17.00 | Not reported | 5.0 | 29.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 14.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 5.00 | Not reported | 5.0 | 29.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 9.50 | Not reported | 5.0 | 56.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 43.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 6.50 | Not reported | 5.0 | 20.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 2.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 2.00 | Not reported | 2.0 | 151.6 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 56.45 | Not reported | 7.7 | 205.1 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 20.60 | Not reported | 2.7 | 150.5 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 8.05 | Not reported | 2.0 | 278.8 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.30 | Not reported | 2.0 | 200.5 | Not reported |
Interleukin-6: Cycle 1; 4 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 4 |
| Part 1: PF-06863135 50 mcg/kg IV | 5 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 6.50 | Not reported | 5.0 | 8.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 7.00 | Not reported | 5.0 | 9.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 16.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 106.00 | Not reported | 5.0 | 206.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 73.00 | Not reported | 15.0 | 813.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 54.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 12.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.00 | Not reported | 5.0 | 7.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 15.50 | Not reported | 5.0 | 71.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 3.5 | 21.7 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 8.95 | Not reported | 2.0 | 20.0 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 58.70 | Not reported | 5.5 | 303.8 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 22.95 | Not reported | 3.2 | 187.4 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 7.45 | Not reported | 2.0 | 292.6 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.25 | Not reported | 2.0 | 165.0 | Not reported |
Interleukin-6: Cycle 1; 8 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 2 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 4 |
| Part 1: PF-06863135 50 mcg/kg IV | 5 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 5 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 11 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.50 | Not reported | 5.0 | 6.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 6.50 | Not reported | 5.0 | 8.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 40.00 | Not reported | 5.0 | 327.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 25.00 | Not reported | 5.0 | 263.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.00 | 33.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 8.00 | Not reported | 5.0 | 54.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 46.50 | Not reported | 5.0 | 67.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 184.50 | Not reported | 12.0 | 342.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 12.00 | Not reported | 5.0 | 33.6 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 24.85 | Not reported | 2.0 | 2080.9 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 52.50 | Not reported | 6.9 | 125.1 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 35.00 | Not reported | 5.1 | 174.8 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 12.80 | Not reported | 2.0 | 634.1 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.00 | Not reported | 2.0 | 621.5 | Not reported |
Interleukin-6: Cycle 1; 24 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 5 |
| Part 1: PF-06863135 50 mcg/kg IV | 5 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 3 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 7.00 | Not reported | 5.0 | 9.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 8.00 | Not reported | 5.0 | 11.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 163.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 5.00 | Not reported | 5.0 | 45.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 6.00 | Not reported | 5.0 | 18.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 7.00 | Not reported | 5.0 | 64.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 9.00 | Not reported | 5.0 | 13.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 16.50 | Not reported | 6.0 | 51.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 29.00 | Not reported | 13.0 | 209.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 21.50 | Not reported | 5.0 | 976.8 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 31.25 | Not reported | 2.3 | 250.0 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 129.65 | Not reported | 10.5 | 631.3 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 38.35 | Not reported | 3.5 | 250.3 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 12.15 | Not reported | 2.0 | 577.6 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.90 | Not reported | 2.0 | 78.7 | Not reported |
Interleukin-6: Cycle 1; 72 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 1 |
| Part 1: PF-06863135 30 mcg/kg IV | 5 |
| Part 1: PF-06863135 50 mcg/kg IV | 5 |
| Part 1: PF-06863135 80 mcg/kg SC | 5 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 5 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 8.50 | Not reported | 5.0 | 12.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 56.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 7.00 | Not reported | 5.0 | 37.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 5.00 | Not reported | 5.0 | 11.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 10.00 | Not reported | 5.0 | 13.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 6.00 | Not reported | 5.0 | 9.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 10.50 | Not reported | 5.0 | 74.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 11.0 | Not reported | 5.0 | 946.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 18.50 | Not reported | 5.0 | 224.2 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 7.20 | Not reported | 2.0 | 45.1 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 89.20 | Not reported | 11.1 | 161.3 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 30.45 | Not reported | 2.0 | 170.4 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 12.25 | Not reported | 2.0 | 188.3 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 32.75 | Not reported | 2.0 | 1239.3 | Not reported |
Interferon-gamma: Cycle 0; 0 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 7 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
Interferon-gamma: Cycle 0; 2 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 7 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
Interferon-gamma: Cycle 0; 4 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 7 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 4.20 | Not reported | 4.2 | 13.8 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 4.20 | Not reported | 2.2 | 18.3 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 4.20 | Not reported | 4.2 | 12.8 | Not reported |
Interferon-gamma: Cycle 0; 8 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 10.30 | Not reported | 4.2 | 487.8 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 7.20 | Not reported | 4.2 | 34.6 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 4.20 | Not reported | 4.2 | 26.3 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 4.20 | Not reported | 4.2 | 106.1 | Not reported |
Interferon-gamma: Cycle 0; 24 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 7 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 5.00 | Not reported | 4.2 | 28.4 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 7.40 | Not reported | 4.2 | 17.4 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 4.20 | Not reported | 4.2 | 25.6 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 4.20 | Not reported | 4.2 | 23.1 | Not reported |
Interferon-gamma: Cycle 1; 0 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 5 |
| Part 1: PF-06863135 50 mcg/kg IV | 6 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 5.00 | Not reported | 5.0 | 7.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 5.00 | Not reported | 5.0 | 164.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 4.2 | 5.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 4.20 | Not reported | 4.2 | 5.9 | Not reported |
Interferon-gamma: Cycle 1; 2 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 4 |
| Part 1: PF-06863135 50 mcg/kg IV | 4 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 4.2 | 5.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 4.20 | Not reported | 4.2 | 4.9 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 4.20 | Not reported | 4.2 | 7.3 | Not reported |
Interferon-gamma: Cycle 1; 4 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 4 |
| Part 1: PF-06863135 50 mcg/kg IV | 5 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 9.00 | Not reported | 5.0 | 13.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 10.00 | Not reported | 5.0 | 33.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 4.2 | 5.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 4.20 | Not reported | 4.2 | 19.0 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 4.20 | Not reported | 4.2 | 5.2 | Not reported |
Interferon-gamma: Cycle 1; 8 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 2 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 4 |
| Part 1: PF-06863135 50 mcg/kg IV | 5 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 11 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 8.50 | Not reported | 5.0 | 39.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 5.00 | Not reported | 5.0 | 16.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.50 | Not reported | 5.0 | 8.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 5.50 | Not reported | 5.0 | 22.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 4.2 | 6.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 4.20 | Not reported | 4.2 | 56.9 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 4.20 | Not reported | 4.2 | 5.5 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 4.20 | Not reported | 4.2 | 7.0 | Not reported |
Interferon-gamma: Cycle 1; 24 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 5 |
| Part 1: PF-06863135 50 mcg/kg IV | 5 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 5.00 | Not reported | 5.0 | 9.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 7.00 | Not reported | 5.0 | 12.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 5.00 | Not reported | 5.0 | 20.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 5.0 | 12.1 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 4.20 | Not reported | 4.2 | 5.9 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 4.20 | Not reported | 4.2 | 20.4 | Not reported |
Interferon-gamma: Cycle 1; 72 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 1 |
| Part 1: PF-06863135 30 mcg/kg IV | 5 |
| Part 1: PF-06863135 50 mcg/kg IV | 5 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 4.2 | 5.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 4.20 | Not reported | 0.4 | 4.2 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 4.20 | Not reported | 4.2 | 4.2 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 4.20 | Not reported | 4.2 | 8.4 | Not reported |
Tumor necrosis factor-alpha: Cycle 0; 0 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 7 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 1.70 | Not reported | 1.7 | 1.7 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 1.70 | Not reported | 1.7 | 17.7 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.00 | Not reported | 1.7 | 2.3 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 1.70 | Not reported | 1.7 | 1.7 | Not reported |
Tumor necrosis factor-alpha: Cycle 0; 2 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 7 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 1.70 | Not reported | 1.7 | 2.8 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 1.70 | Not reported | 1.7 | 75.6 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 1.70 | Not reported | 1.7 | 3.5 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.35 | Not reported | 1.7 | 6.2 | Not reported |
Tumor necrosis factor-alpha: Cycle 0; 4 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 7 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 3.30 | Not reported | 1.7 | 27.7 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 2.50 | Not reported | 1.7 | 164.2 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.60 | Not reported | 1.7 | 9.7 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 1.70 | Not reported | 1.7 | 8.9 | Not reported |
Tumor necrosis factor-alpha: Cycle 0; 8 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 9.70 | Not reported | 1.7 | 46.2 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 7.40 | Not reported | 1.7 | 39.2 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 3.05 | Not reported | 1.7 | 39.1 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 1.75 | Not reported | 1.7 | 114.2 | Not reported |
Tumor necrosis factor-alpha: Cycle 0; 24 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 0 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 0 |
| Part 1: PF-06863135 1 mcg/kg IV | 0 |
| Part 1: PF-06863135 3 mcg/kg IV | 0 |
| Part 1: PF-06863135 10 mcg/kg IV | 0 |
| Part 1: PF-06863135 30 mcg/kg IV | 0 |
| Part 1: PF-06863135 50 mcg/kg IV | 0 |
| Part 1: PF-06863135 80 mcg/kg SC | 0 |
| Part 1: PF-06863135 130 mcg/kg SC | 0 |
| Part 1: PF-06863135 215 mcg/kg SC | 0 |
| Part 1: PF-06863135 360 mcg/kg SC | 0 |
| Part 1: PF-06863135 600 mcg/kg SC | 0 |
| Part 1: PF-06863135 1000 mcg/kg SC | 0 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 7 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 13 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 3.80 | Not reported | 1.7 | 9.1 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 3.80 | Not reported | 1.7 | 15.1 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 3.15 | Not reported | 1.7 | 4.2 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 2.30 | Not reported | 1.7 | 8.5 | Not reported |
Tumor necrosis factor-alpha: Cycle 1; 0 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 5 |
| Part 1: PF-06863135 50 mcg/kg IV | 6 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 41.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 5.00 | Not reported | 5.0 | 25.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 5.00 | Not reported | 5.0 | 37.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 1.7 | 16.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 1.70 | Not reported | 1.7 | 18.4 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 1.70 | Not reported | 1.7 | 2.2 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 1.70 | Not reported | 1.7 | 10.3 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 3.15 | Not reported | 1.7 | 4.6 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 1.70 | Not reported | 1.7 | 3.3 | Not reported |
Tumor necrosis factor-alpha: Cycle 1; 2 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 4 |
| Part 1: PF-06863135 50 mcg/kg IV | 4 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 5.00 | Not reported | 5.0 | 8.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 8.50 | Not reported | 5.0 | 21.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 1.7 | 15.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 1.70 | Not reported | 1.7 | 25.5 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 1.70 | Not reported | 1.7 | 1.7 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 1.80 | Not reported | 1.7 | 14.7 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.55 | Not reported | 1.7 | 4.1 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 1.70 | Not reported | 1.7 | 6.5 | Not reported |
Tumor necrosis factor-alpha: Cycle 1; 4 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 4 |
| Part 1: PF-06863135 50 mcg/kg IV | 5 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 11.0 | Not reported | 5.0 | 70.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 8.00 | Not reported | 5.0 | 138.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 1.7 | 12.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 1.70 | Not reported | 1.7 | 147.3 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 1.70 | Not reported | 1.7 | 2.7 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 1.70 | Not reported | 1.7 | 6.3 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.80 | Not reported | 1.7 | 4.0 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 1.70 | Not reported | 1.7 | 4.0 | Not reported |
Tumor necrosis factor-alpha: Cycle 1; 8 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 2 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 4 |
| Part 1: PF-06863135 50 mcg/kg IV | 6 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 11 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 5.00 | Not reported | 5.0 | 6.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 5.00 | Not reported | 5.0 | 12.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 6.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 6.50 | Not reported | 5.0 | 35.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 8.00 | Not reported | 5.0 | 11.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 1.7 | 27.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 1.70 | Not reported | 1.7 | 458.0 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 1.70 | Not reported | 1.7 | 1.9 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 1.70 | Not reported | 1.7 | 11.6 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 1.70 | Not reported | 1.7 | 5.3 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 1.70 | Not reported | 1.4 | 5.8 | Not reported |
Tumor necrosis factor-alpha: Cycle 1; 24 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 2 |
| Part 1: PF-06863135 30 mcg/kg IV | 5 |
| Part 1: PF-06863135 50 mcg/kg IV | 5 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.00 | Not reported | 5.0 | 7.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 5.00 | Not reported | 5.0 | 12.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 1.7 | 9.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 1.70 | Not reported | 1.7 | 2.0 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 1.70 | Not reported | 1.7 | 2.1 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 2.45 | Not reported | 1.7 | 8.0 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 2.90 | Not reported | 1.7 | 4.1 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 1.70 | Not reported | 1.7 | 6.2 | Not reported |
Tumor necrosis factor-alpha: Cycle 1; 72 hours
| Group | Source count |
|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2 |
| Part 1: PF-06863135 0.3 mcg/kg IV | 3 |
| Part 1: PF-06863135 1 mcg/kg IV | 2 |
| Part 1: PF-06863135 3 mcg/kg IV | 3 |
| Part 1: PF-06863135 10 mcg/kg IV | 1 |
| Part 1: PF-06863135 30 mcg/kg IV | 5 |
| Part 1: PF-06863135 50 mcg/kg IV | 5 |
| Part 1: PF-06863135 80 mcg/kg SC | 6 |
| Part 1: PF-06863135 130 mcg/kg SC | 4 |
| Part 1: PF-06863135 215 mcg/kg SC | 4 |
| Part 1: PF-06863135 360 mcg/kg SC | 4 |
| Part 1: PF-06863135 600 mcg/kg SC | 6 |
| Part 1: PF-06863135 1000 mcg/kg SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 6 |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 12 |
| Part 1C: PF-06863135 + Lenalidomide SC | 4 |
| Part 1D: PF-06863135 + Pomalidomide SC | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 0.3 mcg/kg IV | 5.00 | Not reported | 5.0 | 15.0 | Not reported |
| Part 1: PF-06863135 1 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 3 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 10 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 30 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 50 mcg/kg IV | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 80 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 130 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 215 mcg/kg SC | 5.00 | Not reported | 5.0 | 10.0 | Not reported |
| Part 1: PF-06863135 360 mcg/kg SC | 5.00 | Not reported | 5.0 | 5.0 | Not reported |
| Part 1: PF-06863135 600 mcg/kg SC | 5.00 | Not reported | 1.7 | 5.0 | Not reported |
| Part 1: PF-06863135 1000 mcg/kg SC | 1.70 | Not reported | 1.7 | 3.4 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 1.70 | Not reported | 1.7 | 4.2 | Not reported |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 1.70 | Not reported | 1.7 | 6.7 | Not reported |
| Part 1C: PF-06863135 + Lenalidomide SC | 3.85 | Not reported | 1.7 | 6.9 | Not reported |
| Part 1D: PF-06863135 + Pomalidomide SC | 1.70 | Not reported | 1.7 | 3.6 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG013
- lower Limit
- 2.1
- upper Limit
- 2.1
- value
- 2.10
- group Id
- OG014
- lower Limit
- 2.1
- upper Limit
- 2.1
- value
- 2.10
- group Id
- OG015
- lower Limit
- 2.1
- upper Limit
- 2.1
- value
- 2.10
- group Id
- OG016
- lower Limit
- 2.1
- upper Limit
- 2.1
- value
- 2.10
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- group Id
- OG008
- value
- 0
- group Id
- OG009
- value
- 0
- group Id
- OG010
- value
- 0
- group Id
- OG011
- value
- 0
- units
- Participants
- title
- Interleukin-2: Cycle 0; 0 hours
- categories
- measurements
- group Id
- OG013
- lower Limit
- 2.1
- upper Limit
- 9.1
- value
- 2.10
- group Id
- OG014
- lower Limit
- 2.1
- upper Limit
- 55.0
- value
- 2.10
- group Id
- OG015
- lower Limit
- 2.1
- upper Limit
- 2.1
- value
- 2.10
- group Id
- OG016
- lower Limit
- 2.1
- upper Limit
- 10.5
- value
- 2.10
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- group Id
- OG008
- value
- 0
- group Id
- OG009
- value
- 0
- group Id
- OG010
- value
- 0
- group Id
- OG011
- value
- 0
- units
- Participants
- title
- Interleukin-2: Cycle 0; 2 hours
- categories
- measurements
- group Id
- OG013
- lower Limit
- 2.1
- upper Limit
- 19.7
- value
- 2.70
- group Id
- OG014
- lower Limit
- 2.1
- upper Limit
- 247.4
- value
- 3.60
- group Id
- OG015
- lower Limit
- 2.1
- upper Limit
- 6.5
- value
- 2.10
- group Id
- OG016
- lower Limit
- 2.1
- upper Limit
- 20.9
- value
- 2.40
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- group Id
- OG008
- value
- 0
- group Id
- OG009
- value
- 0
- group Id
- OG010
- value
- 0
- group Id
- OG011
- value
- 0
- units
- Participants
- title
- Interleukin-2: Cycle 0; 4 hours
- categories
- measurements
- group Id
- OG013
- lower Limit
- 2.1
- upper Limit
- 487.8
- value
- 14.30
- group Id
- OG014
- lower Limit
- 2.1
- upper Limit
- 118.1
- value
- 17.90
- group Id
- OG015
- lower Limit
- 2.1
- upper Limit
- 82.0
- value
- 2.10
- group Id
- OG016
- lower Limit
- 2.1
- upper Limit
- 1063.8
- value
- 2.10
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- group Id
- OG008
- value
- 0
- group Id
- OG009
- value
- 0
- group Id
- OG010
- value
- 0
- group Id
- OG011
- value
- 0
- units
- Participants
- title
- Interleukin-2: Cycle 0; 8 hours
- categories
- measurements
- group Id
- OG013
- lower Limit
- 2.1
- upper Limit
- 12.2
- value
- 2.10
- group Id
- OG014
- lower Limit
- 2.1
- upper Limit
- 15.5
- value
- 2.10
- group Id
- OG015
- lower Limit
- 2.1
- upper Limit
- 2.3
- value
- 2.10
- group Id
- OG016
- lower Limit
- 2.1
- upper Limit
- 7.1
- value
- 2.10
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- group Id
- OG008
- value
- 0
- group Id
- OG009
- value
- 0
- group Id
- OG010
- value
- 0
- group Id
- OG011
- value
- 0
- units
- Participants
- title
- Interleukin-2: Cycle 0; 24 hours
- categories
- measurements
- group Id
- OG000
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG001
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG002
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG003
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG004
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG005
- lower Limit
- 5.0
- upper Limit
- 24.0
- value
- 5.00
- group Id
- OG006
- lower Limit
- 5.0
- upper Limit
- 37.0
- value
- 5.00
- group Id
- OG007
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG008
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG009
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG010
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG011
- lower Limit
- 2.1
- upper Limit
- 5.0
- value
- 5.00
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 2
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 6
- group Id
- OG007
- value
- 6
- group Id
- OG008
- value
- 4
- group Id
- OG009
- value
- 4
- group Id
- OG010
- value
- 4
- group Id
- OG011
- value
- 6
- units
- Participants
- title
- Interleukin-2: Cycle 1; 0 hours
- categories
- measurements
- group Id
- OG000
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG001
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG002
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG003
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG004
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG005
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG006
- lower Limit
- 5.0
- upper Limit
- 112.0
- value
- 12.50
- group Id
- OG007
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG008
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG009
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG010
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG011
- lower Limit
- 2.1
- upper Limit
- 5.0
- value
- 5.00
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 2
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 4
- group Id
- OG007
- value
- 6
- group Id
- OG008
- value
- 4
- group Id
- OG009
- value
- 4
- group Id
- OG010
- value
- 4
- group Id
- OG011
- value
- 6
- units
- Participants
- title
- Interleukin-2: Cycle 1; 2 hours
- categories
- measurements
- group Id
- OG000
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG001
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG002
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG003
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG004
- lower Limit
- 5.0
- upper Limit
- 6.0
- value
- 5.50
- group Id
- OG005
- lower Limit
- 5.0
- upper Limit
- 80.0
- value
- 53.00
- group Id
- OG006
- lower Limit
- 21.0
- upper Limit
- 202.0
- value
- 83.00
- group Id
- OG007
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG008
- lower Limit
- 5.0
- upper Limit
- 12.0
- value
- 5.00
- group Id
- OG009
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG010
- lower Limit
- 5.0
- upper Limit
- 7.0
- value
- 5.50
- group Id
- OG011
- lower Limit
- 2.1
- upper Limit
- 6.7
- value
- 5.00
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 2
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 5
- group Id
- OG007
- value
- 6
- group Id
- OG008
- value
- 4
- group Id
- OG009
- value
- 4
- group Id
- OG010
- value
- 4
- group Id
- OG011
- value
- 6
- units
- Participants
- title
- Interleukin-2: Cycle 1; 4 hours
- categories
- measurements
- group Id
- OG000
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG001
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG002
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG003
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG004
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG005
- lower Limit
- 5.0
- upper Limit
- 43.0
- value
- 11.0
- group Id
- OG006
- lower Limit
- 5.0
- upper Limit
- 52.0
- value
- 5.00
- group Id
- OG007
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG008
- lower Limit
- 5.0
- upper Limit
- 50.0
- value
- 5.00
- group Id
- OG009
- lower Limit
- 5.0
- upper Limit
- 15.0
- value
- 8.50
- group Id
- OG010
- lower Limit
- 5.0
- upper Limit
- 39.0
- value
- 12.50
- group Id
- OG011
- lower Limit
- 2.1
- upper Limit
- 20.0
- value
- 5.00
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 2
- group Id
- OG004
- value
- 2
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 5
- group Id
- OG007
- value
- 6
- group Id
- OG008
- value
- 4
- group Id
- OG009
- value
- 4
- group Id
- OG010
- value
- 4
- group Id
- OG011
- value
- 6
- units
- Participants
- title
- Interleukin-2: Cycle 1; 8 hours
- categories
- measurements
- group Id
- OG000
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG001
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG002
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG003
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG004
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG005
- lower Limit
- 5.0
- upper Limit
- 9.0
- value
- 5.00
- group Id
- OG006
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG007
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG008
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG009
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG010
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG011
- lower Limit
- 2.1
- upper Limit
- 5.0
- value
- 5.00
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 2
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 5
- group Id
- OG007
- value
- 6
- group Id
- OG008
- value
- 4
- group Id
- OG009
- value
- 4
- group Id
- OG010
- value
- 4
- group Id
- OG011
- value
- 6
- units
- Participants
- title
- Interleukin-2: Cycle 1; 24 hours
- categories
- measurements
- group Id
- OG000
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG001
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG002
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG003
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG004
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG005
- lower Limit
- 5.0
- upper Limit
- 14.0
- value
- 5.00
- group Id
- OG006
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG007
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG008
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG009
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG010
- lower Limit
- 5.0
- upper Limit
- 5.0
- value
- 5.00
- group Id
- OG011
- lower Limit
- 2.1
- upper Limit
- 5.0
- value
- 5.00
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 1
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 5
- group Id
- OG007
- value
- 6
- group Id
- OG008
- value
- 4
- group Id
- OG009
- value
- 4
- group Id
- OG010
- value
- 4
- group Id
- OG011
- value
- 6
- units
- Participants
- title
- Interleukin-2: Cycle 1; 72 hours
- categories
- measurements
- group Id
- OG013
- lower Limit
- 2.0
- upper Limit
- 4.9
- value
- 2.00
- group Id
- OG014
- lower Limit
- 2.0
- upper Limit
- 17.4
- value
- 2.00
- group Id
- OG015
- lower Limit
- 2.0
- upper Limit
- 2.9
- value
- 2.00
- group Id
- OG016
- lower Limit
- 2.0
- upper Limit
- 2.5
- value
- 2.00
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- group Id
- OG008
- value
- 0
- group Id
- OG009
- value
- 0
- group Id
- OG010
- value
- 0
- group Id
- OG011
- value
- 0
- units
- Participants
- title
- Interleukin-6: Cycle 0; 0 hours
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 2
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 6
- group Id
- OG007
- value
- 6
- group Id
- OG008
- value
- 4
- group Id
- OG009
- value
- 4
- group Id
- OG010
- value
- 4
- group Id
- OG011
- value
- 6
- units
- Participants
- description
- The concentration of Interleukin-2, Interleukin-6, Interferon-gamma and tumor necrosis factor-alpha were measured in this outcome measure. Cycle = C.
- dispersion Type
- Full Range
- groups
- description
- Participants with relapsed/refractory advanced multiple myeloma (MM) received PF-06863135 at a dose of 0.1 microgram/kilogram (mcg/kg) as an intravenous (IV) infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
- id
- OG000
- title
- Part 1: PF-06863135 0.1 mcg/kg IV
- description
- Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 0.3 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
- id
- OG001
- title
- Part 1: PF-06863135 0.3 mcg/kg IV
- description
- Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 1 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
- id
- OG002
- title
- Part 1: PF-06863135 1 mcg/kg IV
- description
- Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 3 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
- id
- OG003
- title
- Part 1: PF-06863135 3 mcg/kg IV
- description
- Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 10 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
- id
- OG004
- title
- Part 1: PF-06863135 10 mcg/kg IV
- description
- Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 30 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
- id
- OG005
- title
- Part 1: PF-06863135 30 mcg/kg IV
- description
- Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 50 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
- id
- OG006
- title
- Part 1: PF-06863135 50 mcg/kg IV
- description
- Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 80 mcg/kg as a subcutaneous (SC) injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
- id
- OG007
- title
- Part 1: PF-06863135 80 mcg/kg SC
- description
- Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 130 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
- id
- OG008
- title
- Part 1: PF-06863135 130 mcg/kg SC
- description
- Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 215 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
- id
- OG009
- title
- Part 1: PF-06863135 215 mcg/kg SC
- description
- Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 360 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
- id
- OG010
- title
- Part 1: PF-06863135 360 mcg/kg SC
- description
- Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 600 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.
- id
- OG011
- title
- Part 1: PF-06863135 600 mcg/kg SC
- param Type
- MEDIAN
- population Description
- The Pharmacodynamic (PD)/Biomarker analysis set included all enrolled participants with at least 1 of the PD/Biomarkers evaluated at pre- and/or post-dose. Here, "Number Analyzed" signifies participants evaluable for specified rows.
- reporting Status
- POSTED
- time Frame
- Part 1: C1 (0, 2, 4 & 8 hours [h] post dose on Day [D] 1, 24h post dose on D2, 72h post dose on D3); Part 1.1, 1C & 1D: C0 (0, 2, 4 & 8h post dose on D1, 24h post dose on D2); C1 (0, 2, 4 & 8h post dose on D1, 24h post dose on D2, 72h post dose on D3)
- title
- Part 1: Concentration of Soluble Cytokines in Serum
- type
- SECONDARY
- unit Of Measure
- Picogram per milliliter
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice